BRPI0412458A - composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada - Google Patents

composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada

Info

Publication number
BRPI0412458A
BRPI0412458A BRPI0412458-8A BRPI0412458A BRPI0412458A BR PI0412458 A BRPI0412458 A BR PI0412458A BR PI0412458 A BRPI0412458 A BR PI0412458A BR PI0412458 A BRPI0412458 A BR PI0412458A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pharmacologically active
release agent
micronized form
orally dosed
Prior art date
Application number
BRPI0412458-8A
Other languages
English (en)
Inventor
Shoufeng Li
Anasuya Ashok Ghosh
Simon David Bateman
Moise Azria
Alan Edward Royce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412458A publication Critical patent/BRPI0412458A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS ORALMENTE DOSADAS COMPREENDENDO UM AGENTE DE LIBERAçãO NA FORMA MICRONIZADA". A presente inenção refere-se a composições farmacêuticas sólidas e métodos para seu uso adequado para a liberação oral de agentes farmacologicamente ativos, por exemplo, peptídeos, compreendendo uma quantidade terapeuticamente eficaz de um agente farmacologicamente ativo; uma crospovidona ou povidona; e um agente de liberação para o referido agente farmacologicamente ativo são descritos. As composições utilizam as formas micronizadas do agente de liberação que fornecem biodisponibilidade realçada de agentes farmacologicamente ativos, particularmente calcitonina.
BRPI0412458-8A 2003-07-11 2004-07-09 composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada BRPI0412458A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48649503P 2003-07-11 2003-07-11
PCT/EP2004/007584 WO2005004900A1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Publications (1)

Publication Number Publication Date
BRPI0412458A true BRPI0412458A (pt) 2006-10-17

Family

ID=34062133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412458-8A BRPI0412458A (pt) 2003-07-11 2004-07-09 composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada

Country Status (15)

Country Link
US (3) US20070065505A1 (pt)
EP (1) EP1651248B1 (pt)
JP (1) JP5032844B2 (pt)
CN (1) CN1809377B (pt)
AT (1) ATE442158T1 (pt)
AU (1) AU2004255458B2 (pt)
BR (1) BRPI0412458A (pt)
CA (1) CA2529604C (pt)
DE (1) DE602004023093D1 (pt)
ES (1) ES2330638T3 (pt)
HK (1) HK1089950A1 (pt)
MX (1) MXPA06000446A (pt)
PL (1) PL1651248T3 (pt)
PT (1) PT1651248E (pt)
WO (1) WO2005004900A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001418A (es) * 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
SG165397A1 (en) 2005-09-19 2010-10-28 Emisphere Tech Inc Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
ES2426485T3 (es) * 2006-08-31 2013-10-23 Novartis Ag Composiciones farmacéuticas que comprenden hGH para administración oral
AR062925A1 (es) * 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
PT2215047E (pt) 2007-11-02 2014-01-20 Emisphere Tech Inc Processo para o tratamento da deficiência de vitamina b12
NZ602032A (en) * 2010-02-24 2014-11-28 Emisphere Tech Inc Oral b12 therapy
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
CA2868188A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
MX2023012437A (es) 2021-04-22 2023-11-07 Civi Biopharma Inc Administracion oral de oligonucleotidos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
CN1809377A (zh) 2006-07-26
US20080234179A1 (en) 2008-09-25
PT1651248E (pt) 2009-11-10
AU2004255458A1 (en) 2005-01-20
US8748383B2 (en) 2014-06-10
US8435946B2 (en) 2013-05-07
ES2330638T3 (es) 2009-12-14
PL1651248T3 (pl) 2010-02-26
CA2529604C (en) 2012-05-08
WO2005004900A1 (en) 2005-01-20
HK1089950A1 (en) 2006-12-15
ATE442158T1 (de) 2009-09-15
JP5032844B2 (ja) 2012-09-26
AU2004255458B2 (en) 2007-09-13
DE602004023093D1 (de) 2009-10-22
US20070065505A1 (en) 2007-03-22
CA2529604A1 (en) 2005-01-20
CN1809377B (zh) 2010-08-04
EP1651248A1 (en) 2006-05-03
MXPA06000446A (es) 2006-04-07
US20130230593A1 (en) 2013-09-05
JP2009513528A (ja) 2009-04-02
EP1651248B1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
NO20032511D0 (no) Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
AR033711A1 (es) Composiciones farmaceuticas
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CL2004000564A1 (es) Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
NO20064808L (no) Orale matrixformuleringer med licarbazepin
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2007011958A3 (en) Intraoral dosage forms of glucagon
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
HRP20070081T5 (en) Nasal pharmaceutical composition of piribedil
WO2007035816A3 (en) Paroxetine compositions
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
BRPI0602614A (pt) utilização de amido desramificado na extrusão - esferonização de pelotas farmacêuticas
AR064419A1 (es) Composiciones farmaceuticas
ECSP024344A (es) Composiciones farmaceuticas
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
BRPI0500420A (pt) composição estável para substáncia farmacologicamente ativa
HUP0500270A2 (en) Pharmacologically active peptide derivatives, process for their preparation and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]